BAYRY Quote, Financials, Valuation and Earnings

BioNTech SE has a net margin of -41.96% compared to Bayer AG's net margin of 15.91%. Bayer AG's return on equity of -2.79% beat BioNTech SE's return on equity of -2.35%.

Bayer AG has a consensus price target of --, signalling upside risk potential of 54.58%. On the other hand BioNTech SE has an analysts' consensus of $137.54 which suggests that it could grow by 21.63%. Given that Bayer AG has higher upside potential than BioNTech SE, analysts believe Bayer AG is more attractive than BioNTech SE.

Bayer AG has a beta of 1.041, which suggesting that the stock is 4.07% more volatile than S&P 500. In comparison BioNTech SE has a beta of 0.217, suggesting its less volatile than the S&P 500 by 78.349%.

Bayer AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.6%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bayer AG pays -80.89% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.

Bayer AG quarterly revenues are $11B, which are larger than BioNTech SE quarterly revenues of $1.4B. Bayer AG's net income of -$4.6B is lower than BioNTech SE's net income of $217.9M. Notably, Bayer AG's price-to-earnings ratio is -- while BioNTech SE's PE ratio is 184.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bayer AG is 0.38x versus 8.26x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.

CureVac NV has a net margin of -41.96% compared to Bayer AG's net margin of 68.44%. Bayer AG's return on equity of -2.79% beat CureVac NV's return on equity of 21.3%.

Bayer AG has a consensus price target of --, signalling upside risk potential of 54.58%. On the other hand CureVac NV has an analysts' consensus of $7.38 which suggests that it could grow by 153.19%. Given that CureVac NV has higher upside potential than Bayer AG, analysts believe CureVac NV is more attractive than Bayer AG.

Bayer AG has a beta of 1.041, which suggesting that the stock is 4.07% more volatile than S&P 500. In comparison CureVac NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Bayer AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.6%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bayer AG pays -80.89% of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend.

Bayer AG quarterly revenues are $11B, which are larger than CureVac NV quarterly revenues of $543.2M. Bayer AG's net income of -$4.6B is lower than CureVac NV's net income of $371.8M. Notably, Bayer AG's price-to-earnings ratio is -- while CureVac NV's PE ratio is 5.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bayer AG is 0.38x versus 1.09x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.

InflaRx NV has a net margin of -41.96% compared to Bayer AG's net margin of -14092.9%. Bayer AG's return on equity of -2.79% beat InflaRx NV's return on equity of -61.55%.

Bayer AG has a consensus price target of --, signalling upside risk potential of 54.58%. On the other hand InflaRx NV has an analysts' consensus of $8.04 which suggests that it could grow by 258.31%. Given that InflaRx NV has higher upside potential than Bayer AG, analysts believe InflaRx NV is more attractive than Bayer AG.

Bayer AG has a beta of 1.041, which suggesting that the stock is 4.07% more volatile than S&P 500. In comparison InflaRx NV has a beta of 1.675, suggesting its more volatile than the S&P 500 by 67.534%.

Bayer AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.6%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bayer AG pays -80.89% of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.

Bayer AG quarterly revenues are $11B, which are larger than InflaRx NV quarterly revenues of $136.2K. Bayer AG's net income of -$4.6B is lower than InflaRx NV's net income of -$19.2M. Notably, Bayer AG's price-to-earnings ratio is -- while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bayer AG is 0.38x versus 716.25x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.

Immatics NV has a net margin of -41.96% compared to Bayer AG's net margin of -16.95%. Bayer AG's return on equity of -2.79% beat Immatics NV's return on equity of -16.88%.

Bayer AG has a consensus price target of --, signalling upside risk potential of 54.58%. On the other hand Immatics NV has an analysts' consensus of -- which suggests that it could grow by 144.53%. Given that Immatics NV has higher upside potential than Bayer AG, analysts believe Immatics NV is more attractive than Bayer AG.

Bayer AG has a beta of 1.041, which suggesting that the stock is 4.07% more volatile than S&P 500. In comparison Immatics NV has a beta of 0.743, suggesting its less volatile than the S&P 500 by 25.688%.

Bayer AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.6%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bayer AG pays -80.89% of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend.

Bayer AG quarterly revenues are $11B, which are larger than Immatics NV quarterly revenues of $55.6M. Bayer AG's net income of -$4.6B is lower than Immatics NV's net income of -$9.4M. Notably, Bayer AG's price-to-earnings ratio is -- while Immatics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bayer AG is 0.38x versus 5.50x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.